1. Home
  2. FBK vs MIRM Comparison

FBK vs MIRM Comparison

Compare FBK & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBK
  • MIRM
  • Stock Information
  • Founded
  • FBK 1906
  • MIRM 2018
  • Country
  • FBK United States
  • MIRM United States
  • Employees
  • FBK N/A
  • MIRM N/A
  • Industry
  • FBK Major Banks
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FBK Finance
  • MIRM Health Care
  • Exchange
  • FBK Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • FBK 2.4B
  • MIRM 2.5B
  • IPO Year
  • FBK 2016
  • MIRM 2019
  • Fundamental
  • Price
  • FBK $49.82
  • MIRM $52.45
  • Analyst Decision
  • FBK Hold
  • MIRM Strong Buy
  • Analyst Count
  • FBK 5
  • MIRM 11
  • Target Price
  • FBK $50.20
  • MIRM $57.00
  • AVG Volume (30 Days)
  • FBK 133.3K
  • MIRM 548.9K
  • Earning Date
  • FBK 04-14-2025
  • MIRM 02-26-2025
  • Dividend Yield
  • FBK 1.52%
  • MIRM N/A
  • EPS Growth
  • FBK N/A
  • MIRM N/A
  • EPS
  • FBK 2.48
  • MIRM N/A
  • Revenue
  • FBK $443,569,000.00
  • MIRM $307,028,000.00
  • Revenue This Year
  • FBK N/A
  • MIRM $83.04
  • Revenue Next Year
  • FBK $8.78
  • MIRM $27.22
  • P/E Ratio
  • FBK $20.09
  • MIRM N/A
  • Revenue Growth
  • FBK N/A
  • MIRM 112.14
  • 52 Week Low
  • FBK $33.35
  • MIRM $23.14
  • 52 Week High
  • FBK $58.88
  • MIRM $54.23
  • Technical
  • Relative Strength Index (RSI)
  • FBK 37.20
  • MIRM 64.07
  • Support Level
  • FBK $51.54
  • MIRM $51.02
  • Resistance Level
  • FBK $52.99
  • MIRM $53.76
  • Average True Range (ATR)
  • FBK 1.22
  • MIRM 2.04
  • MACD
  • FBK -0.28
  • MIRM 0.03
  • Stochastic Oscillator
  • FBK 4.34
  • MIRM 73.31

About FBK FB Financial Corporation

FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: